{"id":525730,"date":"2021-08-10T06:03:22","date_gmt":"2021-08-10T10:03:22","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/itamar-medical-reports-second-quarter-2021-financial-results\/"},"modified":"2021-08-10T06:03:22","modified_gmt":"2021-08-10T10:03:22","slug":"itamar-medical-reports-second-quarter-2021-financial-results","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/itamar-medical-reports-second-quarter-2021-financial-results\/","title":{"rendered":"Itamar Medical Reports Second Quarter 2021 Financial Results"},"content":{"rendered":"
\n

\n
\n – Revenues Increased 41% Year-over-Year to $12.6 Million –<\/em>
\n <\/strong>\n <\/p>\n

\n
\n – U.S. WatchPAT<\/em>
\n <\/strong>
\n
\n
\n TM<\/em>
\n <\/strong>
\n <\/sup>
\n
\n Revenues Increased 53% Year-over-Year to $10.1 Million –<\/em>
\n <\/strong>\n <\/p>\n

\n
\n – Raised Full Year 2021 Revenue Guidance to a Range of $53 Million to $54 Million –<\/em>
\n <\/strong>\n <\/p>\n

\n
\n – Company to Host Conference Call Today at 8:00 am ET, 3:00 pm IT – <\/em>
\n <\/strong>\n <\/p>\n

CAESAREA, Israel, Aug. 10, 2021 (GLOBE NEWSWIRE) — Itamar Medical Ltd. (Nasdaq and TASE: ITMR), a leading medical device and digital health company focused on the integration of sleep apnea management into the cardiac patient care pathway, today reported unaudited financial results for the second quarter of 2021.<\/p>\n

\u201cOur second quarter results demonstrated further growth as our WatchPAT\u2122 technology continued to gain recognition as a safe and effective method for home-based sleep apnea testing,\u201d said Gilad Glick, President and Chief Executive Officer of Itamar Medical. \u201cCore sleep in the U.S. continues to be our most significant growth driver, with double digit growth in nearly every region during the quarter. We also began to see the benefit of the recent elimination of the G-code loophole in Medicare Administrative Contractors (MACs) covering about 60% of Medicare beneficiaries, paving the way for further share gains and materially enhancing our competitive market positioning. In our Cardiology business, we were pleased to see the American Heart Association publish a formal statement on the importance of sleep apnea management in cardiac care for the first time. We are very encouraged by our increasing opportunity to be a meaningful part of this estimated $2.7 billion market in the U.S.\u201d<\/p>\n

\u201cWe see continuing momentum as we enter the second half of 2021, giving us the confidence to raise our guidance for full year revenues. Investing for long-term growth remains top of mind and importantly, we have the financial resources to do so,\u201d concluded Glick.<\/p>\n

\n Second Quarter 2021 Highlights and Recent Achievements<\/strong>\n <\/p>\n